OptiBiotix Health PLC
OPTI
Company Profile
Business description
OptiBiotix Health PLC is engaged in the field of healthcare. As a life science company, its prime focus lies in researching the area of biotechnology. Its activities include the identification of microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology, deriving potential health benefits. The company derives majority of the revenue from the sale of Functional Fibres. The company markets its products in the United Kingdom under trademark names such as OptiBiotix, SweetBiotix, and SkinBioTherapeutics.
Contact
Innovation Centre, Innovation Way
Heslington
YorkYO10 5DG
GBRT: +44 1904435100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
10
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks
Moated AI-proof tech play hiding in the ASX 100
ChatGPT and large language models should be a tailwind for this company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.40 | 19.00 | -0.21% |
| CAC 40 | 8,157.82 | 69.50 | -0.84% |
| DAX 40 | 24,128.98 | 26.47 | -0.11% |
| Dow JONES (US) | 49,230.71 | 79.61 | -0.16% |
| FTSE 100 | 10,379.08 | 77.93 | -0.75% |
| HKSE | 25,978.07 | 62.87 | 0.24% |
| NASDAQ | 24,836.60 | 398.10 | 1.63% |
| Nikkei 225 | 59,716.18 | 575.95 | 0.97% |
| NZX 50 Index | 12,874.94 | 9.99 | -0.08% |
| S&P 500 | 7,165.08 | 56.68 | 0.80% |
| S&P/ASX 200 | 8,786.50 | 12.10 | -0.14% |
| SSE Composite Index | 4,079.90 | 13.35 | -0.33% |